BioXcel Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
BioXcel Therapeutics, Inc. (BTAI) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 6.04 million shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-22.
Discontinued › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2024-03-22
- BioXcel Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2023-03-31 was 5.87M shares, a 22.71% increase year-over-year.
- BioXcel Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2022-03-31 was 4.78M shares, a 17.44% increase year-over-year.
- BioXcel Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2021-03-31 was 4.07M shares.
- BioXcel Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2023 was 6.04M shares, a 14.32% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2022 was 5.28M shares, a 32.00% increase from fiscal 2021.
- BioXcel Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2021 was 4.00M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | 6.04M shares 10-K · filed 2024-03-22 | ||||
| 2023-09-30 | 5.69M shares 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | 5.80M shares 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | 5.87M shares 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | 5.28M shares 10-K · filed 2024-03-22 | 5.00M shares 10-K · filed 2023-03-16 | |||
| 2022-09-30 | 4.99M shares 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | 4.92M shares 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | 4.78M shares 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | 4.00M shares 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | 4.15M shares 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | 4.04M shares 10-Q · filed 2022-08-11 | ||||
| 2021-03-31 | 4.07M shares 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |